US2008152672A1PendingUtilityA1

Methods for treating gluteal muscle

Assignee: ALLERGAN INCPriority: Sep 3, 2004Filed: Mar 4, 2008Published: Jun 26, 2008
Est. expirySep 3, 2024(expired)· nominal 20-yr term from priority
Inventors:Eric R. First
A61P 43/00A61P 21/00A61Q 19/00A61K 2800/91A61K 8/64A61K 38/4893C12Y 304/24069A61K 39/02A61K 38/46
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for treating a buttock deformity or for preventing development of a buttock deformity by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a buttock deformity or to the vicinity of a buttock deformity.

Claims

exact text as granted — not AI-modified
1 . A method for treating an underdeveloped gluteal muscle, the method comprising the step of administering a  botulinum  toxin underneath a buttock fold of a patient having an underdeveloped gluteal muscle, thereby treating the underdeveloped gluteal muscle. 
     
     
         2 . The method of  claim 1 , wherein the  botulinum  toxin is selected from the group consisting of  botulinum  toxin types A, B, C, D, E, F and G. 
     
     
         3 . The method of  claim 1 , wherein the  botulinum  toxin is a  botulinum  toxin type A. 
     
     
         4 . The method of  claim 1 , wherein the  botulinum  toxin is administered in an amount of between about 1 unit and about 3,000 units. 
     
     
         5 . A method for treating an underdeveloped gluteal muscle, the method comprising the steps of administering between 1 and about 3,000 units of  botulinum  toxin type A underneath a buttock, thereby treating the underdeveloped gluteal muscle. 
     
     
         6 . The method of  claim 1 , wherein the  botulinum  toxin is  botulinum  toxin type A and is administered no less than about 5 units to about 2000 units per injection site. 
     
     
         7 . The method of  claim 1 , wherein administration of said  botulinum  toxin treats the underdeveloped gluteal muscle for between about 2 weeks to 5 years. 
     
     
         8 . The method of  claim 1 , wherein the  botulinum  toxin is  botulinum  toxin type B and is administered no less than about 200 units to about 25000 units per injection site. 
     
     
         9 . The method of  claim 1 , wherein the  botulinum  toxin is administered in an amount of between about 10 −3  units/kg and about 35 units/kg of patient weight.

Join the waitlist — get patent alerts

Track US2008152672A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.